Extended Data Fig. 10: Comparison of monthly counts in incident CVD medications (antihypertensives, lipid-lowering medications, T2DM and insulin) observed in all individuals and after exclusion of individuals identified as a fatality in England.
From: The impact of the COVID-19 pandemic on cardiovascular disease prevention and management
a) all individuals: b) excluding individuals identified as COVID-19; c) excluding individuals who died from any cause after 1st April 2018 representing an analysis of individuals alive for the duration of the study period. Vertical dotted lines indicate the timing of the first, second and third national lockdowns on 26th March 2020, 5th November 2020 and 6th January 2021, respectively.
